CN110536900B - 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 - Google Patents

调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 Download PDF

Info

Publication number
CN110536900B
CN110536900B CN201880022469.1A CN201880022469A CN110536900B CN 110536900 B CN110536900 B CN 110536900B CN 201880022469 A CN201880022469 A CN 201880022469A CN 110536900 B CN110536900 B CN 110536900B
Authority
CN
China
Prior art keywords
ser
thr
val
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880022469.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110536900A (zh
Inventor
R·巴利加
D·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of CN110536900A publication Critical patent/CN110536900A/zh
Application granted granted Critical
Publication of CN110536900B publication Critical patent/CN110536900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880022469.1A 2017-04-07 2018-04-06 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 Active CN110536900B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483087P 2017-04-07 2017-04-07
US62/483,087 2017-04-07
PCT/US2018/026474 WO2018187702A2 (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Publications (2)

Publication Number Publication Date
CN110536900A CN110536900A (zh) 2019-12-03
CN110536900B true CN110536900B (zh) 2024-06-11

Family

ID=63713537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880022469.1A Active CN110536900B (zh) 2017-04-07 2018-04-06 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区

Country Status (11)

Country Link
US (2) US11401337B2 (https=)
EP (1) EP3607091A4 (https=)
JP (3) JP2020512820A (https=)
KR (1) KR102696143B1 (https=)
CN (1) CN110536900B (https=)
AU (1) AU2018248336B2 (https=)
CA (1) CA3055790A1 (https=)
IL (1) IL268901B2 (https=)
MX (1) MX2019011986A (https=)
SG (1) SG11201908051RA (https=)
WO (1) WO2018187702A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
US20210380701A1 (en) * 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
JP2022544405A (ja) * 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
AU2023216348A1 (en) * 2022-02-03 2024-06-20 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
US20250326844A1 (en) 2022-04-07 2025-10-23 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
CN105441455A (zh) * 2015-10-21 2016-03-30 重庆市畜牧科学院 一种嵌合核酸分子及其在人源化抗体制备中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
DK1814913T3 (en) 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
US9416496B2 (en) * 2013-10-16 2016-08-16 Georgia-Pacific Consumer Products Lp Method for reducing the bulk and increasing the density of a tissue product
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
WO2015129651A1 (ja) * 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
WO2017053469A2 (en) * 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
MX2019000799A (es) 2016-07-20 2019-06-03 Igm Biosciences Inc Moleculas de union a gitr multimericas y usos de las mismas.
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
EP3759229A4 (en) 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
US20210380701A1 (en) 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
CN105441455A (zh) * 2015-10-21 2016-03-30 重庆市畜牧科学院 一种嵌合核酸分子及其在人源化抗体制备中的应用

Also Published As

Publication number Publication date
JP2023085503A (ja) 2023-06-20
IL268901A (en) 2019-10-31
IL268901B1 (en) 2025-07-01
EP3607091A4 (en) 2021-01-20
JP2020512820A (ja) 2020-04-30
AU2018248336A1 (en) 2019-09-26
AU2018248336B2 (en) 2024-10-03
SG11201908051RA (en) 2019-09-27
CA3055790A1 (en) 2018-10-11
MX2019011986A (es) 2019-11-07
KR102696143B1 (ko) 2024-08-21
IL268901B2 (en) 2025-11-01
US20210147567A1 (en) 2021-05-20
WO2018187702A2 (en) 2018-10-11
JP2024177479A (ja) 2024-12-19
EP3607091A2 (en) 2020-02-12
US11401337B2 (en) 2022-08-02
CN110536900A (zh) 2019-12-03
KR20190137821A (ko) 2019-12-11
US20220340676A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
CN110536900B (zh) 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
JP7499813B2 (ja) 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
JP6793655B2 (ja) Ｃｄ２０結合分子およびその使用方法
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
US20220306760A1 (en) Igm glycovariants
JP2024508709A (ja) 抗ｃｄ１２３結合分子及びその使用法
JP2025506341A (ja) 抗ｃｄ３８結合分子及びその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant